With funding and business development support from the Blavatnik Biomedical Accelerator, a research team’s lab discovery propelled to startup success.

GC Therapeutics (GCTx), a Harvard startup, announced its launch to scale and its technology TFome™, the world’s first “plug and play” induced pluripotent stem cell (iPSC) programming platform for cell therapies in multiple therapeutic areas. 

First anticipated spinout from the alliance, Circle Therapeutics, to develop novel muscle stem cell therapies for a variety of skeletal muscle disorders